BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24936582)

  • 1. Combined chemoradiotherapy with gemcitabine in patients with locally advanced inoperable transitional cell carcinoma of the urinary bladder and/or in patients ineligible for surgery: a phase I trial.
    De Santis M; Bachner M; Cerveny M; Kametriser G; Steininger T; Königsberg R; Schratter-Sehn A; Sedlmayer F; Dittrich C
    Ann Oncol; 2014 Sep; 25(9):1789-1794. PubMed ID: 24936582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer.
    Caffo O; Fellin G; Graffer U; Valduga F; Bolner A; Luciani L; Tomio L; Galligioni E
    Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1310-6. PubMed ID: 14630267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer.
    Sangar VK; McBain CA; Lyons J; Ramani VA; Logue JP; Wylie JP; Clarke NW; Cowan RA
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):420-5. PubMed ID: 15667962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial.
    Kent E; Sandler H; Montie J; Lee C; Herman J; Esper P; Fardig J; Smith DC
    J Clin Oncol; 2004 Jul; 22(13):2540-5. PubMed ID: 15226322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy.
    Herman JM; Smith DC; Montie J; Hayman JA; Sullivan MA; Kent E; Griffith KA; Esper P; Sandler HM
    Urology; 2004 Jul; 64(1):69-73. PubMed ID: 15245938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine, cisplatin, and hyperfractionated accelerated radiotherapy for locally advanced non-small cell lung cancer.
    Zwitter M; Kovac V; Smrdel U; Strojan P
    J Thorac Oncol; 2006 Sep; 1(7):662-6. PubMed ID: 17409933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: long-term results of a phase I trial.
    Oh KS; Soto DE; Smith DC; Montie JE; Lee CT; Sandler HM
    Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):511-7. PubMed ID: 18977098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer.
    Choudhury A; Swindell R; Logue JP; Elliott PA; Livsey JE; Wise M; Symonds P; Wylie JP; Ramani V; Sangar V; Lyons J; Bottomley I; McCaul D; Clarke NW; Kiltie AE; Cowan RA
    J Clin Oncol; 2011 Feb; 29(6):733-8. PubMed ID: 21205754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined chemoradiation therapy with twice-weekly gemcitabine and cisplatin for organ preservation in muscle-invasive bladder cancer: long-term results of a phase 1 trial.
    Azria D; Riou O; Rebillard X; Thezenas S; Thuret R; Fenoglietto P; Pouessel D; Culine S
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):853-9. PubMed ID: 24368064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of gemcitabine plus palliative radiation therapy for advanced lung cancer.
    Choi B; Robins HI; Schiller J; Mehta M
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):175-9. PubMed ID: 18305938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypofractionated intensity modulated radiation therapy in combined modality treatment for bladder preservation in elderly patients with invasive bladder cancer.
    Turgeon GA; Souhami L; Cury FL; Faria SL; Duclos M; Sturgeon J; Kassouf W
    Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):326-31. PubMed ID: 24411604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group.
    Gogna NK; Matthews JH; Turner SL; Mameghan H; Duchesne GM; Spry N; Berry MP; Keller J; Tripcony L;
    Radiother Oncol; 2006 Oct; 81(1):9-17. PubMed ID: 17011058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study.
    Van Laethem JL; Demols A; Gay F; Closon MT; Collette M; Polus M; Houbiers G; Gastelblum P; Gelin M; Houtte PV; Closset J
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):974-80. PubMed ID: 12829132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
    Shelley M; Cleves A; Wilt TJ; Mason M
    Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study.
    Eisbruch A; Shewach DS; Bradford CR; Littles JF; Teknos TN; Chepeha DB; Marentette LJ; Terrell JE; Hogikyan ND; Dawson LA; Urba S; Wolf GT; Lawrence TS
    J Clin Oncol; 2001 Feb; 19(3):792-9. PubMed ID: 11157033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance.
    Addeo R; Caraglia M; Bellini S; Abbruzzese A; Vincenzi B; Montella L; Miragliuolo A; Guarrasi R; Lanna M; Cennamo G; Faiola V; Del Prete S
    J Clin Oncol; 2010 Feb; 28(4):543-8. PubMed ID: 19841330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
    Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A
    Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer.
    Ikeda M; Okada S; Tokuuye K; Ueno H; Okusaka T
    Br J Cancer; 2002 May; 86(10):1551-4. PubMed ID: 12085203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant therapy in pancreatic cancer: Phase I trial of radiation dose escalation with concurrent full-dose gemcitabine.
    Allen AM; Zalupski MM; Robertson JM; Eckhauser FE; Simone D; Brown D; Hejna G; Normolle D; Lawrence TS; McGinn CJ
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1461-7. PubMed ID: 15275733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy.
    Hagan MP; Winter KA; Kaufman DS; Wajsman Z; Zietman AL; Heney NM; Toonkel LM; Jones CU; Roberts JD; Shipley WU
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):665-72. PubMed ID: 14529770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.